The importance of human epidermal growth factor receptor 2 (HER2) as a prognostic and predictive marker in invasive breast cancer is well established. Accurate assessment of HER2 status is essential to determine optimal treatment options.Breast cancer tumor tissue samples from the VIRGO observational cohort tissue substudy that were locally HER2-negative were retested centrally with both US Food and Drug Administration (FDA)-approved immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assays, using FDA-approved assay cutoffs; results were compared.Of the 552 unique patient samples centrally retested with local HER2-negative results recorded, tumor samples from 22 (4.0
作者:Peter A, Kaufman;Kenneth J, Bloom;Howard, Burris;Julie R, Gralow;Musa, Mayer;Mark, Pegram;Hope S, Rugo;Sandra M, Swain;Denise A, Yardley;Miu, Chau;Deepa, Lalla;Bongin, Yoo;Melissa G, Brammer;Charles L, Vogel
来源:Cancer 2014 年 120卷 17期